Top 10 Finalist Nurses Announced for Inaugural Aster Guardians Global Nursing Award
11.4.2022 16:57:00 EEST | Business Wire | Press release
Aster Guardians Global Nursing Award has just announced its top 10 finalists hailing from across the world. These nurses have been selected from over 24,000 nurses who applied from over 184 countries, through a stringent review process run independently by Ernst & Young LLP, a Screening Jury and a Grand Jury. All applications were evaluated to create a shortlist of 181 which underwent further review to put forward 41 top applications. These 41 applications were then reviewed by the Grand Jury to announce the top 10 finalists. All applicant nurses were asked to submit their applications based on four areas of contribution: Leadership, Research/Innovation, Patient Care and Society/Community Service.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220411005418/en/
The top 10 finalists, who will now undergo further evaluation to claim the grand prize of USD 250,000, are: Anna Qabale Duba from Kenya; Dida Jirma Bulle from Kenya; Francis Michael Fernando from United Kingdom; Jasmine Mohammed Sharaf from United Arab Emirates; Julia Dorothy Downing from United Kingdom; Lincy Padicala Joseph from India, Manju Dhandapani from India; Matthew James Ball from Australia; Rachel Abraham Joseph from United States and Wais Mohammad Qarani from Afghanistan. To know more about the top 10 finalists, please visit: https://www.asterguardians.com/.
Speaking on the top 10 finalists and the upcoming award ceremony to be held on 12th May – International Nurses Day, at The Atlantis, Dubai, Dr. Azad Moopen, Founder Chairman and Managing Director of Aster DM Healthcare said, “With over 7000 nurses as the main pillar of our organization, we at Aster witness their commitment and compassion every single day. During this pandemic, their critical contribution with dedication and sacrifice, putting their own safety and lives at risk, was brought to the forefront globally. We thought that it is appropriate to institute a global level award for the nurses to recognize the members of this noble profession. With over 24,000 nurses who applied, we are overwhelmed by the response received from different parts of the world for the inaugural edition of Aster Guardians Global Nursing Award. It has been a hard task for the eminent Jury members to shortlist the top 10 extraordinary nurses from the large number of applicants. We wish the finalists nominated in the top 10 all the very best for the final evaluation process.”
While one winner will be awarded the grand prize of USD 250,000, the other nine finalists will receive a monetary award. The final round will consist of public voting for each of the nurses starting from 26th April and in-person interview with the Grand Jury members consisting of Mr. Howard Catton - Chief Executive Officer, International Council of Nurses, Switzerland; Prof. Sheila Tlou - Co-Chairperson, Global HIV Prevention Coalition and Ex - Minister of Health & Member of Parliament – Govt. of Botswana; Prof. James Buchan - Adjunct Professor, WHO Collaborating Centre for Nursing; Mr. Muralee Thummarukudy, Acting Head, Resilience to Disasters and Conflicts Global Support Branch, United Nations Environment Programme, Switzerland; and Dr. Carolyn Gomes, Executive Director, Caribbean Vulnerable Communities Coalition (CVC), Jamaica.
About Aster DM Healthcare
Aster DM Healthcare Limited is one of the largest private healthcare service providers operating in GCC and in India. With an inherent emphasis on clinical excellence, we are one of the few entities in the world with a strong presence across primary, secondary, tertiary, and quaternary healthcare through our 27 hospitals, 118 clinics, 323 pharmacies and 66 labs & patient experience centres in seven countries, including India. We have over 24,350 plus dedicated staff including 3,110 doctors and 7,063 nurses across the geographies that we are present in, delivering a simple yet strong promise to our different stakeholders: "We'll treat you well."
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220411005418/en/
Contact information
Lavanya Mandal
Head of PR and Internal Communications, +971528126577
Email: lavanya.mandal@asterdmhealthcare.com
Facebook: https://www.facebook.com/AsterGuardians
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom